Abstract 22P
Background
In the phase 1 GARNET study, Dostarlimab (Dmab) a PD-1 inhibitor, demonstrated clinically meaningful and durable antitumor activity in patients (pts) with advanced/ metastatic mismatch repair deficient endometrial cancer (Adv MMRd EC) after chemotherapy (chemo). Recently, the RUBY trial showed a significant improvement in progression-free survival (PFS) with Dmab plus chemo vs chemo alone, changing the standard of care in the first-line setting of Adv MMRd EC. To date, there are no validated predictive biomarkers of response to Dmab. There is growing evidence that tertiary lymphoid structure (TLS) could be predictive of response and prognostic in early EC. In our pilot study, we aim to determine the predictive value of TLS in Adv MMRd EC.
Methods
Pts with Adv MMRd EC treated with Dmab as a second-line after chemo in GARNET and the French early access program at Institut Paoli-Calmettes were included. Tissue samples from hysterectomy, endometrial or metastasis biopsies were collected. Microscopic examination was performed using paraffin-embedded tissue blocks on HES-stained sections. The presence of TLS was defined by histomorphological and phenotypic (immunohistochemistry) criterias: a dense nodule of more than 200 closely grouped lymphoid cells, with an occasional germinal center; a mixture of CD20+ B cells forming a follicle and surrounded by CD3+ T cells. Mature TLS were defined by the presence of follicular dendritic cells CD23+, CD21+, L1CAM+.
Results
14 pts were included from 12/2017-10/2021. One patient was excluded (tissue sample not evaluable). 11/13 (84%) pts had endometrioid EC. TLS were identified in 6/13 (46%) pts (TLS+) on HES sections. Immunohistochemistry staining confirmed the diagnosis of TLS, but did not detect further TLS. Median PFS : 9 months in pts with TLS vs 3.5 months in pts with no TLS.
Conclusions
Presence of TLS on HES sections seemed associated with better PFS in Adv MMRd EC pts treated with second-line Dmab. HES seemed sufficient to identify TLS, and could in routine practice, help better select MMRd pts that could benefit from Dmab alone. Larger cohorts are required to confirm our observations and explore predictive factors of reponse to Dmab in first-line.
Legal entity responsible for the study
Institut Paoli-Calmettes.
Funding
Has not received any funding.
Disclosure
M. Kfoury: Financial Interests, Personal, Invited Speaker: AZ, GSK. F. Rousseau: Financial Interests, Personal, Financially compensated role: Eisai; Financial Interests, Personal, Other: Viatris. R. Sabatier: Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Invited Speaker: Eisai, Clovis Oncology; Financial Interests, Institutional, Research Grant: AstraZeneca; Non-Financial Interests, Personal, Other, Travel fees: MSD, Novartis; Non-Financial Interests, Personal, Other, Congress fees: GSK. All other authors have declared no conflicts of interest.
Resources from the same session
147P - Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020
Presenter: Geneviève Gueguen Dorbes
Session: Poster Display
148P - HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo
Presenter: Kristel Kemper
Session: Poster Display
149P - HLA/SIRPa bispecifics-A novel multitarget therapeutic strategy to induce potent anti-tumor immune responses
Presenter: anahita rafiei
Session: Poster Display
150P - Chemotherapy in combination with Toll-like receptor agonism promoted antitumor immune response in triple negative breast cancer
Presenter: Eunice Dotse
Session: Poster Display
151P - Tumor organoid-derived TIL therapy for colorectal cancer
Presenter: Marc Leushacke
Session: Poster Display
152P - Discovery of best-in-class dual-acting A2AR/A2BR antagonists that are functional in high adenosine environment
Presenter: Nainesh Katagihallimath
Session: Poster Display
153P - Discovery of a Novel, Dual CD73 and PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer
Presenter: James Levin
Session: Poster Display
154P - Computer-aided drug design based on CLDN4 ligand and its biological evaluation in ovarian cancer
Presenter: Yi Xu
Session: Poster Display
155P - A Phase 1 Study Exploring the Safety and Tolerability of the Small-Molecule PD-L1 Inhibitor INCB099280 in Select Advanced Solid Tumors
Presenter: Hans Prenen
Session: Poster Display
156TiP - The LUNGVAC-study; A randomized phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Elin Marie Stensland
Session: Poster Display